Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Aulos Bioscience, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Neonc Technologies, Inc.
Melanoma Institute Australia
H. Lee Moffitt Cancer Center and Research Institute
ImmunityBio, Inc.
University of Pittsburgh
National Cancer Institute (NCI)
Memgen, Inc.
Incyte Corporation
University Hospital, Essen
Ohio State University Comprehensive Cancer Center
Fate Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Incyte Corporation
MultiVir, Inc.